Business Context and Reporting Period
Company: OS Therapies Inc (OSTX), a clinical-stage biopharmaceutical company focused on ADC and immunotherapy research.
Filing Type: Form 8-K (Current Report)
Date of Report: December 24, 2024 (Event Date)
Reporting Period: Specific event reporting regarding a private placement financing.
Key Financial Metrics and Transaction Details
This filing details a private placement financing rather than standard periodic financial results. Key metrics include:
- Gross Proceeds: $6 million (announced pricing) within a range of $6 million to $10 million.
- Security Type: Units consisting of Series A Senior Convertible Preferred Stock and Warrants.
- Price Per Unit: $4.00.
- Preferred Stock Conversion: Initial conversion price of $4.00 (1:1 ratio).
- Warrant Exercise Price: $4.40 per share.
- Liquidation Preference: 150% of the original issue price for Series A Preferred Stock.
- Placement Fees: 7% cash fee on standard investors and 3% on reduced fee investors, plus agent warrants equal to 7% and 3% of the underlying shares, respectively.
Material Changes and Transaction Structure
The Company entered into a Securities Purchase Agreement to raise capital through the issuance of convertible preferred stock and warrants. Material terms include:
- Stockholder Approval Requirement: The Company must obtain stockholder approval for the transaction within 100 days of closing. If not obtained, meetings must be held every four months until approval is secured.
- Issuance Restrictions: The Company is restricted from issuing additional common stock or variable rate transactions for six months post-closing or until stockholder approval is obtained, whichever is later.
- Mandatory Conversion Triggers: Series A Preferred Stock must convert to common stock upon:
- A qualified public offering raising over $10 million at a price $\ge$ $12.00/share.
- A qualified PIPE financing raising over $20 million at a price $\ge$ $12.00/share.
- A third-party acquisition with cash consideration $\ge$ $12.00/share.
- Daily VWAP exceeding 300% of the conversion price for 20 consecutive trading days with minimum volume of $2.0 million.
- Price Reset Mechanism: Conversion and exercise prices will reset on March 15, 2025 (or 10 business days after stockholder approval if later) to the lower of the 10-day average VWAP or the lowest closing price in the preceding 10 days, subject to a floor of $1.00 and a ceiling of $4.00.
Guidance, Outlook, and Risks
Outlook and Closing: The private placement is expected to close on or about December 31, 2024, subject to customary conditions. The Company has engaged Brookline Capital Markets as the exclusive placement agent.
Risks and Contingencies:
- Dilution Risk: The transaction includes significant warrant coverage and a price reset mechanism that could lower the effective conversion price, potentially diluting existing shareholders.
- Approval Risk: The transaction is contingent upon stockholder approval. Failure to obtain approval could impact the Company's ability to issue the securities or trigger repeated shareholder meetings.
- Market Conditions: The mandatory conversion triggers and price reset are tied to specific market price thresholds ($12.00/share for conversion triggers; $1.00-$4.00 range for reset), creating uncertainty regarding the final capitalization structure.
Investor Verification Checklist
- Verify the final closing date and total gross proceeds raised (target range $6M-$10M).
- Confirm the date and outcome of the special stockholder meeting required for approval.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for detailed anti-dilution provisions.
- Monitor the stock price relative to the $12.00 conversion trigger and the $4.00 reset ceiling/floor.
- Assess the impact of the 150% liquidation preference on existing common shareholders in a liquidation scenario.